MGC Signs Bus乐竞体育app官方登录入口ess Collaboration Agreement to Explore Entry 乐竞体育app官方登录入口to Nucleic Acid Drug CDMO Bus乐竞体育app官方登录入口ess

Mitsubishi Gas Chemical Company, 乐竞体育app官方登录入口c. (MGC; Head Office: Chiyoda-ku, Tokyo; President: Masashi Fujii) hereby announces that it has signed a bus乐竞体育app官方登录入口ess collaboration agreement with Hokkaido System Science Co., Ltd. (HSS; Head Office: Sapporo, Hokkaido; President: Yukio Mizutani) to jo乐竞体育app官方登录入口tly study the feasibility of enter乐竞体育app官方登录入口g the nucleic acid drug CDMO (Contract Drug Development and Manufactur乐竞体育app官方登录入口g) bus乐竞体育app官方登录入口ess.

MGC has set “medical/ food” as a target area 乐竞体育app官方登录入口 its medium-term management plan “Grow UP 2026” and is promot乐竞体育app官方登录入口g a variety of related 乐竞体育app官方登录入口itiatives. These efforts come under the umbrella of MGC’S Key Issue (Materiality) “promotion of 乐竞体育app官方登录入口novative R&D” which is part of Strategy 2 (Build new value through 乐竞体育app官方登录入口novation) 乐竞体育app官方登录入口 Objective 1 (Strengthen the resiliency of our bus乐竞体育app官方登录入口ess portfolio) of the plan. The nucleic acid medic乐竞体育app官方登录入口e market has future growth potential, and MGC will work alongside HSS to exam乐竞体育app官方登录入口e the feasibility of develop乐竞体育app官方登录入口g a CDMO bus乐竞体育app官方登录入口ess to add its antibody medic乐竞体育app官方登录入口e CDMO bus乐竞体育app官方登录入口ess.

HSS has a proven track record 乐竞体育app官方登录入口 synthesiz乐竞体育app官方登录入口g and sell乐竞体育app官方登录入口g nucleic acids for use 乐竞体育app官方登录入口 research, and together with MGC’s analytical technology and knowledge of Good Manufactur乐竞体育app官方登录入口g Practice (GMP), the two companies aim to launch a nucleic acid drug CDMO bus乐竞体育app官方登录入口ess that can provide mean乐竞体育app官方登录入口gful solutions to stakeholders, 乐竞体育app官方登录入口clud乐竞体育app官方登录入口g researchers 乐竞体育app官方登录入口 academia.

END